Artificial intelligence has reached a pivotal milestone by successfully creating drug-like antibodies, signaling a potential transformation in the biopharmaceutical industry. This breakthrough prompts the question: how soon will AI-driven antibody design revolutionize drug development and biopharma practices?
The American Customer Satisfaction Index read 76.1 in August 2026, the same score it held in 2015, so United States customer expectations have held flat for eleven years while complaints hit records and the variable that actually moved was tolerance.
Read More
TLDR: Regulated-industry marketers who build neuromarketing capabilities at pre-launch stage convert compliance...
Read More